Report LibraryAll Reports
Datamonitor Healthcare Trends & Market Access: Big Pharma Licensing Trends, 2014–18
August 20, 2019An analysis of the drug-focused licensing deals (out-licensing and in-licensing) made by Big Pharma companies shows an uptick in partnering from 2014 to 2015, followed by a slight decrease in 2016 that has held steady through 2018. Despite that slight decline, the peer set increased deal volume by roughly 15% between the beginning and the end of the five-year period. Total deal values rose even more, roughly 25%.
This Datamonitor Healthcare report contains a Trends & Market Access module.
|Disease Group Covered:||
Gastroenterology (non inflammatory bowel disease)
Rheumatology (non autoimmune)